Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
Completed · Phase 1
Conditions studied: Cystic Fibrosis
In brief
The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.
Key facts
- Study ID
- NCT07349394
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 18
- Starts
- 2026-01-12
- Expected to finish
- 2026-03-12
- Last updated by the study team
- 2026-04-02
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Altasciences - Kansas City — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.